Hidden blood mutations linked to higher heart disease risk after cancer treatment

About one in five patients with cancer who undergo genetic testing are incidentally found to have mutations in their blood called clonal hematopoiesis of indeterminate potential (CHIP). A study by Vanderbilt Health researchers reveals that it puts them at increased risk for heart disease following cancer treatment.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup